Top 50 Life Science VC (Venture Capital) Funds in United Kingdom in October 2024
A list of 50 VC (Venture Capital) funds that invest in Life science startups based in United kingdom. We rank investors based on the number of investments they made in Life science companies from United kingdom. We update this investor list every month.Top 50 Life Science VC (Venture Capital) Funds in United Kingdom in October 2024
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Seed, Series A, Series B
- United Kingdom, United States, Philippines
Portfolio highlights
- Evoralis — Utilise Our Innovative Enzymes to Efficiently Recycle Plastics Into High-Quality Raw Materials
- PhoreMost — PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savingsonto patients.
- OW Smell Made Digital — OW Smell Made Digital offers software and hardware solutions for controlling smell.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates.
HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Seed, Convertible Note, Pre-Seed
- United States, India, United Kingdom
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Seed, Series A, Funding Round
- United Kingdom, United States, Finland
Portfolio highlights
- FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
- Fractile — Fractile is building chips to run large language models two orders of magnitude faster. Existing hardware is good for training LLMs, but very poorly suited to subsequent inference of the trained model, which is increasingly the dominant workload. A network’s weights need to be moved onto a chip once per word generated, and this movement takes a fewhundred times longer than the subsequent computations themselves. Fractile’s revolutionary approach to fusing computation with memory eliminates this bottleneck, and can scale to allow running the world’s largest models at a global scale.
- Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Funding Round, Series A
- United Kingdom, United States
Portfolio highlights
- HonuWorx — HonuWorx is a technology company providing autonomous systems aimed at lowering both expenses and the environmental impact of operating robotic systems. The company's software technology is an edge-cloud architected communications and control platform that enables geographically distributed stakeholders to see data, collaborate, supervise, andcontrol robotic systems that are beyond line-of-sight.
- Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
- Wave Photonics — Wave Photonics utilizes computational techniques to accelerate integrated photonics product designs.The company is developing a platform that provides optimized designs and streamlined integration between the supply chain using a software tool for predicting the performance and variation of a component for a given fabrication process and anoptimizer to generate a foundry-specific component library.Wave Photonics is headquartered in Bristol, Bristol.
Development Bank of Wales is formed in 2001 by the Welsh Assembly Government. Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Seed, Funding Round, Debt Financing
- United Kingdom, Australia, United States
Portfolio highlights
- PlantSea — PlantSea manufactures and develops sustainable products using seaweed and aquaculture materials. It offers bioplastics items as biodegradable alternatives. PlantSea is based in Gaerwen, England.
- Menna — Be smarter about money and grow faster with Menna. Take control of your business finances today!
- Awen Oncology — Delivering first-in-class therapeutics that target novel, undrugged cancer-specific factors, offering new hope for patients around the world.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- France, United States, United Kingdom
Portfolio highlights
- deepc — The Radiology AI Platform - Your effortless access to AI
- Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
- Micropep Technologies — Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control.
24Haymarket is an investment network which included several highly-experienced private equity and venture capital investors, seasoned entrepreneurs, and senior operators. Investing up to £5 million in growth companies in the UK and Europe. They invested their own capital in direct alignment with entrepreneurs and actively support their growthagenda and join the board of the companies in which they invest. Since inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.
Show more
Investment focus
- Health Care, Software, Information Technology
- Funding Round, Seed, Series A
- United Kingdom, United States
Portfolio highlights
- myGwork — The global recruitment & networking hub for LGBTQ+ professionals. Find jobs in lesbian, gay, bisexual and transgender friendly organisations. Grow your LGBTQ+ professional network. Read the latest LGBTQ+ professional news.
- Previsico — Previsico is a spinOut company from Loughborough University specialising in modelling flooding in real-time, using weather predictions to make street-level flood nowcasts and forecasts. The company's mission is to be the leading global provider of cutting-edge flood prediction that saves lives and livelihoods.Its FloodMap Live producesround the clock street-level flood risk predictions and analytics. Uniquely, these are continuously modelled and updated using a combination of different weather forecasts. This allows the company to map the likelihood of short and long-term surface water events in real-time to the street level.
- Huq Industries — The leading monitoring platform for footfall, dwell, catchment and traffic flows valued by government, retail and real-estate. Used by 50+ councils!
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Series A, Seed, Series B
- United Kingdom, United States, The Netherlands
Portfolio highlights
- Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
- Oxford Endovascular — Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel.This diverts the blood away from the aneurysm, allowing it to heal.
- Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.
The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Seed, Funding Round, Series A
- United Kingdom, Italy, Germany
Portfolio highlights
- ScubaTx — ScubaTx is a breakthrough organ preservation device organ transplant. The ScubaTx device will leverage world-leading expertise in software design to commercialise a proven but unexploited organ preservation technique, Persufflation. ScubaTx will offer healthcare providers significant net savings, an
- Flynotes — Flynotes is a digital software platform helping dentists deliver personalised patient care
- QV Bioelectronics — Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours.
Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.
Show more
Investment focus
- Software, Biotechnology, Health Care
- Funding Round, Seed, Series A
- United Kingdom, United States
Portfolio highlights
- Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
- 1inhaler — 1inhaler operates as a developer of drug delivery device.
- iGii — Integrated Graphene enable better products with a revolutionary design for manufacture process producing the world's highest quality pure 3D Graphene Foam, Gii.
Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.
Show more
Investment focus
- Biotechnology, Software, Health Care
- Grant, Funding Round, Seed
- United Kingdom, United States, Japan
Portfolio highlights
- MiAlgae — MiAlgae is a new-age microalgal production company that aims to revolutionize the £340 billion global livestock feed industry by producing microalgal products – through the remediation of wastewater – as nutrient supplements for fishmeal in livestock feeds. Their microalgal products are high in omegas and proteins, both of which are required forthe production of many livestock feeds, especially in the aquaculture sector.Their production methodology uses circular economy to reduce the operating costs involved in the production of microalgae and as such allows them to compete with other supplements currently on the market.
- Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
- ILC Therapeutics — ILC Therapeutics Ltd is an early-stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Covid-19, Cancer, Atopic Dermatitis, and Psoriasis.
Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. The programme aims to introduce new people to investing and investing in the healthcare/life sciences sector via investor workshops and introduce business angels to investment opportunities from highly-selected and trained companies.With aparticular focus on drug therapies, digital health and medical device technologies, Angels in MedCity brings potential investors together with life sciences experts in a programme aimed at both people who are new to investing and experienced investors who have little or no experience in the life sciences sector. The aim is to build investor understanding in the life sciences sector and support life sciences companies to gain funding to commercialise their ideas.Angels in MedCity has created a community of investors supported through a programme of investor workshops. Using case studies and tips from experienced investors in the field, the workshops explain how to identify and structure a good deal in the life sciences sector, as well as provide expert advice on tax breaks and legal issues.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Seed, Funding Round, Angel
- United Kingdom, United States
Portfolio highlights
- Atelerix — Discover Atelerix's hypothermic hydrogels for eco-friendly, reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples today.
- Clustermarket — The intuitive lab management system for all academic research facilities and industrial laboratories that need to efficiently manage equipment bookings.
- DynamX Medical — DynamX Medical has developed a reliable and inexpensive precancer screening system for rapid tissue biopsy analysis that can be operated point-of-care by nurses.
Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution
Show more
Investment focus
- Software, Health Care, Biotechnology
- Seed, Funding Round, Series A
- United Kingdom, United States
Portfolio highlights
- Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
- Weldfast — Weldfast is a manufacturer and supplier of welding consumables, abrasives, chemicals, premium gas equipment, and safety products.
- EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology
Selvedge Venture operates as a venture capital firm investing for impact in age-related medical conditions.
Show more
Investment focus
- Health Care, Biotechnology, Life Science
- Seed, Pre-Seed, Series A
- United Kingdom, Singapore
Portfolio highlights
- Mesh Bio — Mesh Bio is a digital health startup that is transforming chronic disease management through predictive analytics. Mesh Bio works with healthcare providers and stakeholders to provide innovative solutions that transform health screening and disease management. They translate clinical data and numbers into actionable insights that help patientsbetter manage their health, lifestyle and disease risks.
- Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
- BIOS — BIOS Health is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals.
Speak with our Entrepreneurship Team, who can help you find sources of finance, engage with funders and secure investment to grow your business.
Show more
Investment focus
- Software, Biotechnology, Information Technology
- Funding Round, Seed, Series A
- United Kingdom, United States, France
Portfolio highlights
- Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
- IOTech — Discover IOTech Systems, the open edge data platform for developing, deploying, and managing Industrial Edge applications at scale. Find out more here.
- Administrate — Manage 100% of enterprise training operations with configurable training management software, designed to scale with your organization.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more
Investment focus
- Health Care, Software, Biotechnology
- Series A, Seed, Series B
- Switzerland, Germany, France
Portfolio highlights
- Cubbit — Cubbit is secure encrypted cloud storage with a difference. A distributed cloud that is 100% private and green. Join the Swarm.
- Axelera AI — To accelerate computer vision in edge devices, we offer a powerful, energy-efficient, cost-effective, user-friendly AI hardware and software platform.
- Puraffinity — Puraffinity develops targeted materials for water treatment, focused on forever chemicals called PFAS. Our strategic intent is to provide 1 billion people with PFAS safe water by 2030
Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Seed, Funding Round, Series A
- United Kingdom, Australia, Singapore
Portfolio highlights
- AI-Sight — AI-Sight is a startup that is developing an AI diabetic retinal screening system to deliver WHO-recommended diabetic eye screening services.
- Microplate Dx — Safeguarding against the spread of antimicrobial resistance worldwide.
- GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .
Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.
Show more
Investment focus
- Biotechnology, Therapeutics, Health Care
- Series A, Seed, Series B
- United Kingdom, United States, Germany
Portfolio highlights
- Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
- Curve Therapeutics — Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs.
- Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Seed, Funding Round, Series A
- United Kingdom, United States, Hungary
Portfolio highlights
- Kuano — Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates.
- MGISS — Independently advising on the smarter use of Geospatial data, technology and the digital transformation of field operations.
- Workbuzz — Give your Everyday Heroes a voice with employee surveys. Our flexible and simple survey platform reaches all employees, wherever they are. Book a demo now!
IQ Capital is a Cambridge & London-based VC firm that invests in ‘deep tech’ companies capable of dominating their respective markets on a global scale. Initial investments at Seed and Series A range from £0.5m to £10m, with capacity for follow-on investment up to £30m through the Growth Fund. The team has achieved over 30 exits including toApple, Huawei, Google and Oracle.
Show more
Investment focus
- Software, Artificial Intelligence, Machine Learning
- Seed, Series A, Funding Round
- United Kingdom, United States, The Netherlands
Portfolio highlights
- NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
- Neurovalens — Neurovalens delivers innovative solutions in the field of neuroscience, bioscience and neurophysiology.Neurovalens has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme. The project, recorded on the ERDF beneficiaries’ website, will be implemented over the next one year, undertaking research anddevelopment activities aimed at improving the competitiveness of the business.
- Vsim Technology — Experience the power of next-generation physics simulations with Vsim. Our cutting-edge technology provides realistic and accurate simulations for various industries.
SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Seed, Funding Round
- United States, United Kingdom, Israel
Portfolio highlights
- AstronauTx — AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.
- Sudo Biosciences — Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class.
- Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
We provide venture capital investment for the people, ideas and industries that will change the world. Learn about what we do and the kind of founders we back.
Show more
Investment focus
- Software, Health Care, Artificial Intelligence
- Series A, Seed, Series B
- United Kingdom, United States, Germany
Portfolio highlights
- Desia — Desia provides advanced AI applications for productivity, automation, and analytics for financial services.
- NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
- Puraffinity — Puraffinity develops targeted materials for water treatment, focused on forever chemicals called PFAS. Our strategic intent is to provide 1 billion people with PFAS safe water by 2030
APX Ventures offers digital solutions, including pay-per-click, custom web services, SEO, and cloud services.
Show more
Investment focus
- Software, Artificial Intelligence, Health Care
- Seed, Series A, Pre-Seed
- Germany, Austria, United Kingdom
Portfolio highlights
- sewts — Founded in 2019 and based in Munich, sewts GmbH provides cutting-edge perception software, pushing the boundaries of robotics in processing of easily deformable materials. sewts has developed and demonstrated a unique technology that uses high-precision finite element method (FEM) simulations to efficiently train machine learning algorithms. Theintelligent software solution enables countless applications in industrial automation like the handling of textiles in industrial laundries or the manufacturing of garment. sewts is backed by APEX Ventures, Bayern Kapital, High-Tech Gründerfonds, UnternehmerTUM Initiative for Industrial Innovators and a couple of highly experienced business angels.
- Senisca — Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing.
- CardiaTec Biosciences — CardiaTec is a digital biotechnology venture combining the power of AI and expert talent to redesign cardiovascular drug discovery to deliver the next generation of therapeutics
Playfair is a generalist VC fund with a contrarian approach to pre-seed technology investing. Based in London, Playfair invests across the UK and Europe with an intentionally high conviction, low volume approach: making 6-8 investments a year and preserving time, capital and resource to help companies post-investment. Playfair has backed 70+companies across two funds including Thought Machine, Andela, Mapillary, Recycleye and Orca AI.
Show more
Investment focus
- Software, Artificial Intelligence, E-Commerce
- Seed, Series A, Funding Round
- United Kingdom, United States, France
Portfolio highlights
- Recurse ML — Streamline your development with Recurse, enabling seamless code maintenance with just a single command.
- NetFabric — NetFabric is developing a next-gen network observability platform
- Passionfruit — Join hundreds of the best startups around the world and use Passionfruit to hire freelance marketing specialists on-demand.
Southern Angel Investors Club, combining Surrey investors Club & Angels 5K, are entrepreneurs who understand what new businesses need.
Show more
Investment focus
- Biotechnology, Software, Medical
- Seed, Funding Round, Angel
- United Kingdom
Portfolio highlights
- Celixir — Celixir is a developer of regenerative medicines created to change the lives of patients in need. The company's medicines consists of iMP cells, platelet lysate and PML cells to treat patients with ischaemic heart disease, injured tendons near the surface of the skin and mild to moderate heart failure respectively, enabling medical researchersto discover breakthrough medicines that aim to change the standard of medical care for patients.
- Novastone Media — With its unique asymmetric technology, novastone puts you directly where your clients want to talk to you.
- Geektastic — Geektastic guarantees hiring teams only meet high calibre candidates. Our technical code challenges quickly identify the most talented software engineers.
AlbionVC supports visionary founders with long-term capital and scale-up expertise. Founded in 1996, today we are partners to UK early-stage B2B software and healthcare companies. AlbionVC manages c. $1 billion of venture funds, currently invested in over 50 companies. AlbionVC is the technology investment arm of Albion Capital Group LLP, which isauthorised and regulated by the Financial Conduct Authority.
Show more
Investment focus
- Software, Health Care, Artificial Intelligence
- Series A, Funding Round, Seed
- United Kingdom, United States, France
Portfolio highlights
- tem. — In a few simple steps we can manage your renewable energy needs forever.
- Treefera — Treefera is transforming the way the world approaches forest data and conservation, to create a clear future for the carbon market and the planet.
- Infact Systems — Infact Systems is a company that focuses on bringing affordability and credit information into the 21st century. They facilitate the sharing of real-time, contextual data, primarily in the banking industry. Their mission is to increase responsible financial behavior by providing real-time data for modern credit. They offer integration andcustomization services for HPZone, particularly in terms of connecting with external laboratory systems. Infact Systems also provides services to help women take control of their finances.
In physics, 11.2 km/s is the escape velocity from Earth's gravity. They focus on emerging technologies such as AI, cybersecurity, robotics, quantum, new space, computational therapeutics, synthetic biology. They believe great people are leading indicators of a company's success. 11.2 Capital’s technical background, operationalexperience, and a strong network of amazing advisors and international partners particularly in Asia deliver a unique set of resources to entrepreneurs. While they are happy to help companies across the full range of early-stage company questions, areas where they concentrate include technical recruiting, partnerships (OEM and distribution partnerships for smart hardware companies, data partnerships for data-driven healthcare companies), customer introductions (CISO introductions for security companies, provider introductions for healthcare companies), and follow-on financings.
Show more
Investment focus
- Software, Information Technology, Biotechnology
- Seed, Series A, Series B
- United States, Canada, United Kingdom
Portfolio highlights
- Mantle — Precision metal 3D printers for the tooling industry. 3D printing injection mold, prototype tooling, conformal cooling San Francisco Bay Area
- Thea Energy — Discover Thea Energy, a fusion energy company reinventing the stellarator to create a limitless source of zero emission energy for a sustainable future.
- Coalesce Automation — Coalesce is the only data transformation tool built for scale. Evolve your transformations and empower your entire data team.
Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Funding Round, Seed, Series A
- United Kingdom, United States, France
Portfolio highlights
- Ittybit — Ittybit is a API that enables users to handle rich media in applications. It provides developers with basic techniques for uploading, storing, transforming, and extracting data from video, music, and image files.
- HealthKey — HealthKey is a platform that connects employers and insurers with health providers.
- Noggin HQ — The next generation of credit referencing is coming. Look busy.
Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.
Show more
Investment focus
- Biotechnology, Therapeutics, Medical
- Series A, Series B, Seed
- United Kingdom, United States, Switzerland
Portfolio highlights
- Spur Therapeutics — Spur Therapeutics is a clinical-stage biotechnology business dedicated to creating life-changing medicines for crippling chronic illnesses.
- SwanBio Therapeutics — SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, genetically defined neurological conditions.
- Yellowstone Biosciences — Yellowstone seeks to identify a novel class of frequently expressed antigens that can be therapeutically targeted, With the potential to dramatically improve patient outcomes.
A new model for Venture Capital where every founder we back becomes a co-owner of the fund
Show more
Investment focus
- Software, Biotechnology, Information Technology
- Seed, Series A, Series B
- United Kingdom, Israel, United States
Portfolio highlights
- LabGenius — Finding the next generation of drugs with machine learning, synthetic biology and laboratory automation
- Puraffinity — Puraffinity develops targeted materials for water treatment, focused on forever chemicals called PFAS. Our strategic intent is to provide 1 billion people with PFAS safe water by 2030
- Fractile — Fractile is building chips to run large language models two orders of magnitude faster. Existing hardware is good for training LLMs, but very poorly suited to subsequent inference of the trained model, which is increasingly the dominant workload. A network’s weights need to be moved onto a chip once per word generated, and this movement takes a fewhundred times longer than the subsequent computations themselves. Fractile’s revolutionary approach to fusing computation with memory eliminates this bottleneck, and can scale to allow running the world’s largest models at a global scale.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
- Renalys Pharma — Renalys Pharma is a private, late-stage clinical biopharmaceutical firm in Japan dedicated on developing new therapies that address unmet needs in the management of renal illness in Japanese and Asian patients.
- Zenas BioPharma — Enabling patients with autoimmune diseases to reimagine life
Focused on seeding early stage biotech therapeutics and related AI opportunities. The fund will invest in companies qualifying under EIS and covering novel...
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Seed, Series A, Pre-Seed
- United Kingdom, Hungary
Portfolio highlights
- Healx — At Healx we use AI drug discovery to develop new treatments for rare diseases. We bring treatments from prediction to patient.
- ViaNautis — Precision Solutions
- Pencil Biosciences — Next Generation Genome Editing Tool
Brilliant Ideas. Brilliant People. Brilliant Minds.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Funding Round, Seed, Convertible Note
- United Kingdom, United States, Canada
Portfolio highlights
- 44.01 — We offer a permanent CO2 storage solution using the natural power of mineralisation
- Wittaya Aqua — A better approach to aquaculture management
- Armada Technologies — Armada Technologies created the world's first Passive Air Lubrication technology. This award-winning technology operates in a passive mode and allows for discrete control of system output while completely decoupling system lubrication from ship speed. In doing so, PALS can provide appropriate boundary layer aeration under every operatingstate.
Formic Ventures is a diversified venture capital firm that makes early-stage investments in biotechnology startups focused on human longevity as well as technology startups and companies that make human lives more meaningful.
Show more
Investment focus
- Biotechnology, Health Care, Artificial Intelligence
- Seed, Series A, Funding Round
- United States, United Kingdom, Hong Kong
Portfolio highlights
- Turn.bio — Turn Biotechnologies is a Stanford spinout developing therapies to effectively return mature differentiated cells to a dramatically younger state leaving their differentiated identity unaltered.Turn Biotechnologies surpasses traditional approaches based on single gene/pathway manipulations and tackles the multifaceted manifestation ofcellular age at the organ, tissue, and organismal level to extend the healthspan of people. As a result, age is reset by epigenetically reprogramming cells.
- cheMastery — Echo handles repetitive tasks with accuracy and precision, allowing your chemists to tackle high-value challenges.
- Sampling Human — The mission of Sampling Human is to couple health related decisions to their effects at the single cell level. It is inspired by the founders’ academic and professional efforts to extend what is measurable and to derive what must be measured.The human body is a complex system that cannot be quantified exhaustively or heuristically. Clinicaldiagnosis today is an imprecise art. On average, diagnosis of rare diseases is 5 years delayed with 50% of delays impacting the outcome. Misdiagnosis is far too common with a 66% likelihood of disagreement between experts. We are stuck with symptoms based medicine.The nature of physiological data is to blame. Decisions today are based on fuzzy variables (tired, drowsy, weak, tingling, itchy, etc). Better decisions will require precise knowledge regarding the fundamental physiological units of our bodies, CELLS.
Amadeus Capital Partners, Venture Capital For Technology Companies. We Back Entreprenuers To Win. Contact Our Experienced Team Of Investors Today
Show more
Investment focus
- Software, Artificial Intelligence, Information Technology
- Series B, Seed, Series A
- United Kingdom, United States, Spain
Portfolio highlights
- PhoreMost — PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savingsonto patients.
- Riverlane — Riverlane's mission is to make quantum computing useful far sooner than previously imaginable, starting an era of human progress as significant as the industrial and digital revolutions.
- qomodo — Intelligent IOT Embedded Security. We protect commercial or industrial IOT devices from the threats of the internet. Driven by leading intelligence and machine learning, our anomaly detection allows us to protect even the simplest IOT devices.
Praetura Ventures has been supporting entrepreneurs with more than money since 2011. Click to find out more about how we can help businesses and investors.
Show more
Investment focus
- Software, Health Care, Information Technology
- Funding Round, Seed, Series A
- United Kingdom
Portfolio highlights
- ScubaTx — ScubaTx is a breakthrough organ preservation device organ transplant. The ScubaTx device will leverage world-leading expertise in software design to commercialise a proven but unexploited organ preservation technique, Persufflation. ScubaTx will offer healthcare providers significant net savings, an
- Cytix — Cytix is a vulnerability management software platform and cluster of dedicated pentesters to help you identify & resolve Vulnerabilities. Reach us & get a free trial of tool.
- Ocula Technologies — Harness the power of advanced analytics with our sustainable growth platform enabling brands and retailers to outperform competitors.
Hoxton Ventures focuses on startups that either disrupt existing industries or invent entirely new market categories. Hoxton typically invests between $500,000 and $5 million into pre-seed, seed, and Series A stage companies, and follows its capital through the life of the company.
The firm is based in London and invests all across Europe.
Show more
Investment focus
- Artificial Intelligence, Information Technology, Software
- Seed, Series A, Funding Round
- United Kingdom, United States, Canada
Portfolio highlights
- Cogna — Cogna offers an AI-powered SaaS platform that streamlines the integration of data across several business domains.
- CuspAI — CuspAI is a revolutionary AI startup that is developing a platform for next-generation materials to address global sustainability and renewable energy concerns. CuspAI uses cutting-edge generative AI, deep learning, and molecular simulation to accelerate the material design process. Their platform works similarly to a search engine for materials,allowing users to request certain properties for new materials on demand.
- Malted AI — Malted AI is a developer of a low-code platform enables enterprises to build and deploy large language models-enabled applications at scale, using distillation to inject domain-specific knowledge into smaller, focused models, trained on proprietary data in a secure environment.
Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!
Show more
Investment focus
- Software, Information Technology, SaaS
- Pre-Seed, Seed, Series A
- Singapore, United Kingdom, Australia
Portfolio highlights
- FitFlo — FitFlo brings to life the connected gym experience for Operators, Trainers and Members.
- Mole — Mole is a digital business card and mobile website software. Connect with your clients, promote your business online and much more. Comes with free customised NFC business card.
- Optacloud — Fostering a global AI powered ecosystem to achieve 100% cloud efficacy-> effortlessly, economically and eco-consciously. Dev tools stack for automating the entire development lifecycle of cloud apps across- Build, Deploy & Optimize.
We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more
Investment focus
- Health Care, Artificial Intelligence, Software
- Seed, Pre-Seed, Series A
- United States, United Kingdom, Austria
Portfolio highlights
- Noah Labs — Noah Labs is a compant that creates AI-powered software solutions for medical care and research that help diagnose, manage illnesses, and guide interventions.
- Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
- Lillian Care — Lillian is building a nationwide network of health facilities in Germany.
Molten Ventures is a venture capital company. They invest in software, telecoms, electronics, the internet, MedTech, and cleantech services. They support visionary entrepreneurs who will invent the future.
Show more
Investment focus
- Software, Information Technology, Financial Services
- Series A, Series B, Funding Round
- United Kingdom, United States, Germany
Portfolio highlights
- Aktiia — Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com.
- FintechOS — FintechOS extends your core, letting you innovate banking and insurance products, digital journeys, and back-office workflows without the cost or risk.
- Anima — Anima's online patient triage speeds up the clinical workflow 10x and allows providers to deliver the right care for patients within 24 hours.Millions of patients with serious problems are missed and die every year because there isn’t adequate information flow between medical appointments. Patients submit their problems and requests onAnimainstead of waiting for an appointment, and Anima sends an actionable report to their provider with trends, risks and recommendations.
Wren is an angel investor in science, engineering and software. They founded Wren in 2011 and have invested in 50 companies so far.Wren is well known in the early stage investment community and has co-invested with a wide range of both angel and institutional investors. From software and semiconductors to genome editing, and from medical devicesto satellites, they are interested in sectors where technical ingenuity and hard work can produce long term value. They look for people with a deep understanding of their markets. The founders they invest in are smart and they get things done.Wren typically invests £50,000 to £200,000 per funding round. Difficult problems take time to solve, so they are patient with their investments. Their aim is to get deals done and they take a pragmatic approach to doing so.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Funding Round, Series A
- United Kingdom
Portfolio highlights
- Spotta — Spotta's smart pest systems help pest control monitor and identify pests. Solutions for hospitality, care homes, agriculture, farming and forestry.
- PharmEnable — At PharmEnable Therapeutics we access the inaccessible. We are re-imagining small molecule therapeutics through AI.
- Bastion Therapeutics — Bastion Therapeutics - Enhancing Tregs To Restore Balance In Inflammatory Disorders Treg cell therapy for inflammatory disorders and autoimmune diseases.
R42 Group is a venture fund and an institute which invents, invests and informs covering AI, deep science, 5G mobile, biotech and fintech.
Show more
Investment focus
- Biotechnology, Health Care, Information Technology
- Seed, Funding Round, Pre-Seed
- United Kingdom, United States, Austria
Portfolio highlights
- Healx — At Healx we use AI drug discovery to develop new treatments for rare diseases. We bring treatments from prediction to patient.
- xWatts — xWatts is an intelligent energy management software that reduces energy costs and emissions in commercial buildings.
- Senisca — Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing.
We invest in founders building business on the frontier of what is possible. Creator Fund believes...
Show more
Investment focus
- Machine Learning, Software, Artificial Intelligence
- Pre-Seed, Seed, Series A
- United Kingdom, Canada, Israel
Portfolio highlights
- Fairgen — Data-centric approach to debiasing machine learning models and artificial intelligence algorithms.
- Malted AI — Malted AI is a developer of a low-code platform enables enterprises to build and deploy large language models-enabled applications at scale, using distillation to inject domain-specific knowledge into smaller, focused models, trained on proprietary data in a secure environment.
- Helical — Helical is an intermediary platform that offers bioinformaticians free access to the technologies from AI and biological computation.
The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Funding Round, Seed, Series A
- United Kingdom, United States, Israel
Portfolio highlights
- CroBio — Crobio presents an environmentally sustainable solution for reducing global water consumption and preventing agricultural drought.
- QV Bioelectronics — Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours.
- Pencil Biosciences — Next Generation Genome Editing Tool
Partnering with innovative, high-growth companies that support a sustainable future in materials, infrastructure, environmental solutions and industrial systems.
Show more
Investment focus
- Manufacturing, Biotechnology, Renewable Energy
- Seed, Series A, Series B
- United States, United Kingdom, Germany
Portfolio highlights
- INERATEC — INERATEC provides sustainable fuels, gas-to-liquid, power-to-gas and power-to-liquid application products.
- ZwitterCo — ZwitterCo is revolutionizing water & wastewater treatment with cutting-edge membrane technology, along with providing sustainable, high-efficiency solutions.
- Puraffinity — Puraffinity develops targeted materials for water treatment, focused on forever chemicals called PFAS. Our strategic intent is to provide 1 billion people with PFAS safe water by 2030
Martlet Capital is an early-stage investor based in Cambridge, providing patient capital to deep technology and life science startups with high growth potential. Investing in the future.
Show more
Investment focus
- Biotechnology, Software, Health Care
- Seed, Series A, Pre-Seed
- United Kingdom, United States
Portfolio highlights
- Xampla — Xampla: Drop-in replacements for single-use plastic, eliminating plastic pollution. Biodegrade quickly & safely. Named world's most promising cleantech co.
- OctaiPipe — OctaiPipe safeguards critical infrastructure with AIoT devices, enhancing asset health and security while reducing cloud data transfers.
- Infinitopes — Infinitopes is a cancer research organization whose mission is to strengthen the immune system so that it can stop metastases and save lives. The company's platform creates healthcare systems and therapy designs to integrate high-efficiency vector delivery systems with optimal tumor target identification technologies in early-stage clinicaltrials, allowing patients to prevent cancer and tumors from taking their lives
Ahren Innovation Capital is a World Changing Institution. A group of highly diverse, creative and original thinkers, at the cutting edge of their domains.
Show more
Investment focus
- Artificial Intelligence, Biotechnology, Machine Learning
- Series A, Seed, Series B
- United States, United Kingdom, Israel
Portfolio highlights
- ZOE — ZOE analyzes your unique gut, blood fat and blood sugar responses. So you can take back control of your health & weight
- Mentee Robotics — Mentee Robotics combines robotics, sensing, and artificial intelligence to create a humanoid robot with human-like dexterity and perception that can be personalized and adjusted to various surroundings and tasks through natural human contact. It aims to improve productivity and daily operations in both households and warehouses.
- Rubedo Life Sciences — Rubedo Life Sciences is the Premier Longevity Company. Rubedo discovers and develops medicines to keep you biologically young.
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more
Investment focus
- Health Care, Biotechnology, Therapeutics
- Seed, Series A, Series B
- United Kingdom, United States, Australia
Portfolio highlights
- Microbiotica — Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models.
- MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
- Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Seed, Series B
- Australia, United States, United Kingdom
Portfolio highlights
- Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.
- Pheon Therapeutics — Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England.
- Pathios Therapeutics — Pioneering a novel macrophage conditioning approach to delivering breakthrough cancer therapies
The Cambridge Angels are a group of high-net worth investors who have proven experience as successful entrepreneurs in internet, software, technology and bio-technology. Members invest in and mentor high quality start-up and early-stage companies in these sectors in the Cambridge (UK) area and throughout the UK.Typical funding requirements thatthe Cambridge Angels meet are in the range of £50,000 to £500,000 - although it is worth noting that several of their portfolio companies have received more than £1m in funding from their Members over several funding rounds.Their Members have been responsible for a large number of the “Cambridge Phenomenon” success stories over recent years. Therefore, in addition to providing funding for early-stage companies, the Cambridge Angels also offer start-ups the considerable benefit of a wide range of expertise, contacts and directly relevant experience in establishing and growing entrepreneurial businesses successfully.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Seed, Funding Round, Series A
- United Kingdom, United States, Estonia
Portfolio highlights
- xWatts — xWatts is an intelligent energy management software that reduces energy costs and emissions in commercial buildings.
- Qureight — Pioneering data curation to solve complex diseases
- Monument Therapeutics — Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system.
Investors by industry
Energy
Climate
Health Care
Gaming
Hardware
Artificial intelligence
Impact
Proptech
Marketplace
Community
FinTech
Google
Consumer
Biotech
EdTech
Sustainability
Venture Capital
Beauty
B2B
Photography
Finance
Real Estate
Big Data
Web3
Clean Energy
Oil and Gas
Video Games
Social Media
Medical
Email
Food and Beverage
Art
Publishing
Wellness
Music
Education
Mobile
Franchise
Social Network
Payments
Local
Internet
Digital Media
Fashion
Construction
Manufacturing
Organic Food
eSports
Sports
Retail
Enterprise Software
Legal
Android
Financial Services
Platforms
Mobile Advertising
Infrastructure
Biotechnology
Hospitality
Fitness
Wine And Spirits
Travel
Recruiting
Cannabis
CleanTech
Medical Device
Transportation
Crowdfunding
Mobile Apps
InsurTech
Social
Enterprise
Automotive
LGBT
Renewable Energy
Life Science
Theatre
Film
Non Profit
SaaS
Sporting Goods
Software
Restaurants
Social Impact
Celebrity
Agriculture (agtech)
Cryptocurrency
Media (entertainment)
Facebook
Blockchain
Investors by country
India
Germany
South Korea
United Kingdom
Australia
Ireland
New Zealand
Canada
United States
Spain
Indonesia
Singapore
South Africa
Africa
Qatar
Europe
LATAM
Middle East
Sri Lanka
Asia
Armenia
Vietnam
China
Japan
Saudi Arabia
Brazil
Oceania
Czech Republic
Ecuador
Barbados
Costa Rica
Finland
Belarus
France
Estonia
Hong Kong
Denmark
Morocco
Malta
Gibraltar
Mali
Malaysia
Chile
Italy
Bermuda
Belize
Peru
Georgia
Greece
Egypt
Lithuania
Myanmar
Hungary
Lebanon
Kuwait
Cayman Islands
Cambodia
Israel
Ethiopia
Faroe Islands
Panama
Algeria
Ghana
Mexico
Belgium
Kazakhstan
Liberia
Croatia
Jersey
Philippines
Bulgaria
Norway
Bahrain
Turkey
Mauritius
Kenya
Serbia
Rwanda
Liechtenstein
El Salvador
Nicaragua
Venezuela
Ukraine
Dominican Republic
Nigeria
Azerbaijan
Namibia
Iceland
Portugal
Iraq
Bahamas
Sierra Leone
Zimbabwe
United Arab Emirates
Sweden
Honduras
Taiwan
Bolivia
Isle of Man
Luxembourg
Senegal
Albania
Pakistan
Uruguay
Uganda
Tunisia
Grenada
Jordan
Romania
San Marino
Slovenia
Argentina
Bangladesh
Zambia
Uzbekistan
Russian Federation
Seychelles
Thailand
Puerto Rico
Tajikistan
Togo
Poland
Tanzania
Austria
Latvia
Cyprus
Oman
Cameroon
Switzerland
Colombia
Marshall Islands
Guatemala
VC (Venture Capital) Funds in United Kingdom by industry
Transportation
FinTech
Enterprise
Biotech
Health Care
Climate
EdTech
Impact
SaaS
Marketplace
Proptech
Community
Artificial intelligence
Hardware
Gaming
Restaurants
Crowdfunding
Film
Real Estate
Fashion
Venture Capital
Web3
Financial Services
Cryptocurrency
Education
Finance
Payments
Medical Device
Food and Beverage
Organic Food
Wine And Spirits
Medical
Video Games
Internet
Social Media
Social Network
Art
Manufacturing
Music
Android
Digital Media
Blockchain
Legal
Software
Construction
Local
Enterprise Software
Sports
Fitness
Automotive
eSports
Travel
Hospitality
Recruiting
Cannabis
Mobile
Biotechnology
Platforms
Mobile Advertising
Mobile Apps
Retail
Social
Beauty
B2B
Sporting Goods
Photography
Publishing
Big Data
Oil and Gas
Renewable Energy
Clean Energy
Energy
Email
Infrastructure
Wellness
Consumer
Life Science
Theatre
Franchise
Agriculture (agtech)
Media (entertainment)
Non Profit
CleanTech
Facebook
InsurTech
Social Impact
Sustainability